Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level

World Psychiatry

Volumn 10, Issue 2, 2011, Pages 138-151

  De Hert, Marc ^a   Cohen, Dan ^b,c   Bobes, Julio ^d   Cetkovich Bakmas, Marcelo ^e   Leucht, Stefan ^f   Ndetei, David M ^g   Newcomer, John W ^h   Uwakwe, Richard ⁱ   Asai, Itsuo ^j   Möller, Hans Jurgen ^k   Gautam, Shiv ^l   Detraux, Johan ^a   Correll, Christoph U ^m  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Department of Severe Mental Illness   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY OF OVIEDO   (Spain)

^e FAVALORO UNIVERSITY   (Argentina)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF NAIROBI   (Kenya)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NNAMDI AZIKIWE UNIVERSITY   (Nigeria)

^j Japanese Society of Transcultural Psychiatry   (Japan)

^k UNIVERSITY OF MUNICH   (Germany)

^l Medical College   (India)

^m ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Barriers; Health care; Health disparities; Monitoring and treatment guidelines; Physical health; Physical illness; Severe mental illness

Indexed keywords

ANTIDEPRESSANT AGENT; ELECTROLYTE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MOOD STABILIZER; NEUROLEPTIC AGENT; PROLACTIN; THYROID HORMONE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ALCOHOLISM; BLOOD CELL COUNT; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DENTAL HEALTH; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIETARY INTAKE; DISEASE SURVEILLANCE; ELECTROCARDIOGRAM; EXERCISE; FAMILY HISTORY; FUNDING; GLUCOSE BLOOD LEVEL; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH STATUS; HEART DEATH; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INTERHOSPITAL COOPERATION; LIFESTYLE; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MENTAL DISEASE; MENTAL HEALTH CARE; MORBIDITY; MORTALITY; MOTIVATION; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PHYSICAL DISEASE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOLOGIC ASSESSMENT; QT PROLONGATION; RACISM; RESPONSIBILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING; SEDENTARY LIFESTYLE; SEVERE MENTAL ILLNESS; SEXISM; SEXUAL HEALTH; SMOKING; STIGMA; TOBACCO DEPENDENCE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WELLBEING;

EID: 80053138418     PISSN: 17238617     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2051-5545.2011.tb00036.x     Document Type: Review

References (150)

1. De Hert M, Correll CU, Cohen D et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77.
2. Lawrence D, Stephen K. Inequalities in health care provision for people with severe mental illness. J Psychopharmacol (in press).
3. De Hert M, Schreurs V, Vancampfort D et al. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009;8:15-22.
4. Bradford DW, Kim MM, Braxton LE et al. Access to medical care among persons with psychotic and major affective disorders. Psychiatr Serv 2008;59:847-52.
5. Parks J, Svendsen D, Singer P et al (eds). Morbidity and mortality in people with serious mental illness. Alexandria: National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council, 2006.
6. Millar H. Management of physical health in schizophrenia: a stepping stone to treatment success. Eur Neuropsychopharmacol 2008;18:S121-8.
7. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008;69:514-9. (Pubitemid 351792324)
8. Essock SM, Miller AL, Buchanan RW et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49. (Pubitemid 38989085)
9. Bobes J, Alegría AA, Saiz-Gonzalez MD et al. Change in psychiatrists' attitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the Consensus on Physical Health in Patients with Schizophrenia. Eur Psychiatry (in press).
10. Maj M. Physical health in persons with severe mental illness: a public health and ethical priority. World Psychiatry 2009;8:1-2.
11. Saxena S, Sharan P, Garrido M et al. World Health Organization's Mental Health Atlas 2005: implications for policy development. World Psychiatry 2006;5:179-84.
12. World Health Organization. Mental Health Atlas, revised version. Geneva: World Health Organization, 2005.
13. Phelan M, Stradins L, Morrison S. Physical health of people with severe mental illness. BMJ 2001;322:443-4.
14. Robson D, Gray R. Serious mental illness and physical health problems: a discussion paper. Int J Nurs Stud 2007;44:457-66.
15. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006;3:A42.
16. Saraceno B, Van Ommeren M, Batniji R et al. Barriers to improvement of mental health services in low-income and middle-income countries. Lancet 2007;370:1164-74. (Pubitemid 47495949)
17. Kane JM. Creating a health care team to manage chronic medical illnesses in patients with severe mental illness: the public policy perspective. J Clin Psychiatry 2009;70:37-42.
18. Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003;178:S67-S70. (Pubitemid 36591938)
19. Zeber JE, McCarthy JF, Bauer MS et al. Datapoints: self-reported access to general medical and psychiatric care among veterans with bipolar disorder. Psychiatr Serv 2007;58:740. (Pubitemid 46985165)
20. Cradock-O'Leary J, Young AS, Yano EM et al. Use of general medical services by VA patients with psychiatric disorders. Psychiatr Serv 2002;53:874-8. (Pubitemid 34742771)
21. World Health Organization. Mental health and physical health: a call to action. The Mental and Physical Health Platform. Geneva: World Health Organization, 2003.
22. Thornicroft G, Alem A, Dos Santos RA. WPA guidance on steps, obstacles and mistakes to avoid in the implementation of community mental health care. World Psychiatry 2010;9:67-77.
23. Maj M. Mistakes to avoid in the implementation of community mental health care. World Psychiatry 2010;9:65-6.
24. Kendrick T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br J Psychiatry 1996;169:733-9.
25. Brown S, Birtwistle J, Roe L et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701. (Pubitemid 29261358)
26. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-7.
27. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 2007;68:4-7. (Pubitemid 46762117)
28. Brugha TS, Wing JK, Smith BL. Physical health of the long-term mentally ill in the community. Is there unmet need? Br J Psychiatry 1989;155:777-81. (Pubitemid 20086771)
29. Horvitz-Lennon M, Kilbourne AM, Pincus HA. From silos to bridges: meeting the general health care needs of adults with severe mental illnesses. Health Aff 2006;25:659-69. (Pubitemid 43824915)
30. Jeste DV, Gladsjo JA, Lindamer LA et al. Medical comorbidity in schizophrenia. Schizophr Bull 1996;22:413-30. (Pubitemid 26295345)
31. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999;60:10-5. (Pubitemid 29523627)
32. Ananth J. Physical illness and psychiatric disorders. Compr Psychiatry 1984;25:586-93. (Pubitemid 15190592)
33. Hennekens CH, Hennekens AR, Hollar D et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-21. (Pubitemid 41773510)
34. Nasrallah HA, Meyer JM, Goff DC et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22. (Pubitemid 44234064)
35. Goff DC, Sullivan LM, McEvoy JP et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005;80:45-53. (Pubitemid 41587462)
36. Frayne SM, Halanych JH, Miller DR et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med 2005;165:2631-8. (Pubitemid 41785061)
37. Druss BG, Bradford WD, Rosenheck RA et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001;58:565-72. (Pubitemid 32523736)
38. Druss BG, Rosenheck RA, Desai MM et al. Quality of preventive medical care for patients with mental disorders. Med Care 2002;40:129-36.
39. Burns T, Cohen A. Item-of-service payments for general practitioner care of severely mentally ill persons: does the money matter? Br J Gen Pract 1998;48:1415-6. (Pubitemid 28352014)
40. Paton C, Esop R, Young C et al. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004;110:299-305. (Pubitemid 39278989)
41. Greening J. Physical health of patients in rehabilitation and recovery: a survey of case note records. Psychiatr Bull 2005;29:210-2. (Pubitemid 40861945)
42. Lai DW, Chau SB. Effects of service barriers on health status of older Chinese immigrants in Canada. Soc Work 2007;52:261-9.
43. Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry 2007;68:14-8. (Pubitemid 46762119)
44. Sokal J, Messias E, Dickerson FB et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis 2004; 192:421-427. (Pubitemid 38746100)
45. Parks J, Radke AQ (eds). Obesity reduction and prevention strategies for individuals with serious mental illness. Alexandria: National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council, 2008.
46. Fagiolini A, Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry 2009;70:22-9.
47. Druss BG, Von Esenwein SA, Compton MT et al. A randomized trial of medical care management for community mental health settings: the Primary Care Access, Referral, and Evaluation (PCARE) study. Am J Psychiatry 2010;167:151-9.
48. Vreeland B. Bridging the gap between mental and physical health: a multidisciplinary approach. J Clin Psychiatry 2007;68:26-33. (Pubitemid 46762120)
49. National Collaborating Centre for Mental Health Commissioned by the National Institute for Health and Clinical Excellence. Schizophrenia. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). www.guidance.nice.org.uk.
50. Saravane D, Feve B, Frances Y et al. Drawing up guidelines for the attendance of physical health of patients with severe mental illness. Encephale 2009;35:330-9.
51. Kerwin R. Connecting patient needs with treatment management. Acta Psychiatr Scand 2009;438:33-9.
52. Straker D, Correll CU, Kramer-Ginsberg E et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005;162:1217-21. (Pubitemid 40770711)
53. De Hert M, Van Winkel R, Silic A et al. Physical health management in psychiatric settings. Eur Psychiatry 2010;25:S22-8.
54. Heald A, Montejo AL, Millar H et al. Management of physical health in patients with schizophrenia: practical recommendations. Eur Psychiatry 2010;25:S41-5.
55. Correll CU, Manu P, Olshanskiy V et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73.
56. De Hert M, Dobbelaere M, Sheridan EM et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry (in press).
57. Hasnain M, Fredrickson SK, Vieweg WV et al. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep 2010;10:209-16.
58. Marder SR, Essock SM, Miller AL et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49. (Pubitemid 38989085)
59. Wagenknecht LE, Langefeld CD, Scherzinger AL et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2003;52:2490-6. (Pubitemid 37210536)
60. De Vegt F, Dekker JM, Jager A et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 2001;285:2109-13. (Pubitemid 32367828)
61. Wahrenberg H, Hertel K, Leijonhufvud BM et al. Use of waist circumference to predict insulin resistance: retrospective study. BMJ 2005;330:1363-4. (Pubitemid 40839563)
62. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004;24:S1-6. (Pubitemid 39265948)
63. Barnes TR, Paton C, Cavanagh MR et al. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007;33:1397-403. (Pubitemid 350022774)
64. Mackin P, Bishop DR, Watkinson HM. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 2007;7:28.
65. De Hert M, Dekker JM, Wood D et al. Cardiovascular disease and diabetes in people with severe mental illness. Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-24.
66. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
67. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. (Pubitemid 37430158)
68. Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008;23:3-14. (Pubitemid 351166608)
69. International Expert Committee. International Expert Committee report on the role of the AlC assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34
70. Hanssens L, De Hert M, Van Eyck D et al. Usefulness of glycosylated haemoglobin (HbA1c) to screen for diabetes in patients with schizophrenia. Schizophr Res 2006;85:296-7. (Pubitemid 43947546)
71. De Beer K, Michael S, Thacker M et al. Diabetic ketoacidosis and hyperglycaemic hyperosmolar syndrome - clinical guidelines. Nurs Crit Care 2008;13:5-11.
72. Silversides JA, Farling PA. Diabetic ketoacidosis guidelines and protection from aspiration pneumonitis. Diabet Med 2009;26:829.
73. Charles RA, Bee YM, Eng PH et al. Point-of-care blood ketone testing: screening for diabetic ketoacidosis at the emergency department. Singapore Med J 2007;48:986-9. (Pubitemid 351235249)
74. Wilson JF. In clinic. Diabetic ketoacidosis. Ann Intern Med 2010;152:ITC1/1-15.
75. Peuskens J, Pani L, De Hert M et al. Antipsychotics and hyperprolactinemia. Unpublished paper.
76. Peveler RC, Branford D, Citrome L et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008;22:98-103.
77. Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 2004;29:833-46. (Pubitemid 38528763)
78. Bushe C, Yeomans D, Floyd T et al. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol 2008;22:56-62.
79. Tschoner A, Engl J, Rettenbacher MA et al. Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study. J Clin Psychiatry 2009;70:293-4.
80. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45:771-91. (Pubitemid 43932904)
81. Persson K, Axtelius B, Söderfeldt B et al. Oral health-related quality of life and dental status in an outpatient psychiatric population: a multivariate approach. Int J Ment Health Nurs 2010;19:62-70.
82. Nielsen J, Munk-Jørgensen P, Skadhede S et al. Determinants of poor dental care in patients with schizophrenia: a historical, prospective database study. J Clin Psychiatry (in press).
83. British Society for Disability and Oral Health. Oral health care for people with mental health problems - guidelines and recommendations. www.bsdh.org.uk.
84. Waterreus AJ, Laugharne JD. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust 2009;190:185-9.
85. Castle D, Lambert T, Melbourne S et al. A clinical monitoring system for clozapine. Australas Psychiatry 2006;14:156-68. (Pubitemid 44349328)
86. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur J Cardiovasc Prev Rehabil 2007;14:S1-113.
87. Allison DB, Newcomer JW, Dunn AL et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med 2009;36:341-50.
88. Van Winkel R, De Hert M, Van Eyck D et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 2006;67:1493-500. (Pubitemid 44787430)
89. Bamett AH, Mackin P, Chaudhry I et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007;21:357-73. (Pubitemid 47077296)
90. Cahn W, Ramlal D, Bruggeman R et al. Prevention and treatment of somatic complications arising from the use of antipsychotics. Tijdschr Psychiatr 2008;50:579-91.
91. Chrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005;19:102-9. (Pubitemid 44567864)
92. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006;51:492-501. (Pubitemid 44166337)
93. De Hert M, Van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006;21:11-5.
94. De Nayer A, De Hert M, Scheen A et al. Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Clin Pract 2005;9:130-7. (Pubitemid 40874109)
95. Sáiz Ruiz J, Bobes Garcia J, Vallejo Ruiloba J et al. Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry. Actas Esp Psiquiatr 2008;36:251-64.
96. Buckley PF, Miller DD, Singer B et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005;79:281-8. (Pubitemid 41457268)
97. Haupt DW, Rosenblatt LC, Kim E et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009;166:345-53.
98. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
99. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. www.idf.org.
100. Vreeland B. Treatment decisions in major mental illness: weighing the outcomes. J Clin Psychiatry 2007;68:5-11. (Pubitemid 350021617)
101. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Schizophr Bull 2007;33:654-6. (Pubitemid 47343724)
102. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007;1:CD005148.
103. Alvarez-Jiménez M, Hetrick SE, González-Blanch C et al. Nonpharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008;193:101-7.
104. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 1998;97:1095-102.
105. Rich-Edwards JW, Manson JE, Hennekens CH et al. The primary prevention of coronary heart disease in women. N Engl J Med 1995;332:1758-66.
106. Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005;99:1193-204. (Pubitemid 41214540)
107. Brock CM, King DS, Wofford MR et al. Exercise, insulin resistance, and hypertension: a complex relationship. Metab Syndr Relat Disord 2005;3:60-5. (Pubitemid 41136553)
108. Donnelly JE, Blair SN, Jakicic JM et al. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2009;41:459-71.
109. Cormac I. Promoting healthy lifestyles in psychiatric services. In: Physical heath in mental health. Final report of a scoping group. Royal College of Psychiatrists, 2009:62-70.
110. Laurent SM, Simons AD. Sexual dysfunction in depression and anxiety: conceptualizing sexual dysfunction as part of an internalizing dimension. Clin Psychol Rev 2009;29:573-85.
111. Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother 2010;10:1175-200.
112. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9. (Pubitemid 41110453)
113. Stokes C, Peet M. Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms. Nutr Neurosci 2004;7:247-9. (Pubitemid 40123578)
114. McCreadie RG; Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534-9.
115. Menza M, Vreeland B, Minsky S et al. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004;65:471-7.
116. Vreeland B, Minsky S, Menza M et al. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003;54:1155-7. (Pubitemid 36951518)
117. Gabriele JM, Dubbert PM, Reeves RR. Efficacy of behavioral interventions in managing atypical antipsychotic weight gain. Obes Rev 2009;10:442-55.
118. Hill JO, Peters JC, Catenacci VA et al. International strategies to address obesity. Obes Rev 2008;9:41-7. (Pubitemid 351643189)
119. Hill JO, Wyatt HR. Small changes: a big idea for addressing obesity. Obes Manage 2006;2:227-331.
120. Roick C, Fritz-Wieacker A, Matschinger H et al. Health habits of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2007;42:268-76. (Pubitemid 46455733)
121. Faulkner G, Cohn T, Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia. Schizophr Res 2006;82:225-31. (Pubitemid 43290686)
122. US Department of Health and Human Services. Physical activity guidelines for Americans. Washington: US Department of Health and Human Services, 2008.
123. Vancampfort D, Knapen J, De Hert M et al. Cardiometabolic effects of physical activity interventions for people with schizophrenia. Phys Ther Rev 2009;14:388-98.
124. De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005;76:135-57. (Pubitemid 40812332)
125. Garcia-Portilla MP, Saiz PA, Benabarre A et al. Impact of substance use on the physical health of patients with bipolar disorder. Acta Psychiatr Scand 2010;121:437-45.
126. Bobes J, Arango C, Garcia-Garcia M et al. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010;119:101-9.
127. Cormac I, Brown A, Creasey S et al. A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatr Scand 2010;121:393-7.
128. Yeh HC, Duncan BB, Schmidt MI et al. Smoking, smoking cessation, and risk for type 2 diabetes mellitus: a cohort study. Ann Intern Med 2010;152:10-7.
129. Addington J, el-Guebaly N, Campbell W et al. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 1998;155:974-6. (Pubitemid 28307615)
130. George TP, Ziedonis DM, Feingold A et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-42.
131. Weiner E, Ball MP, Summerfelt A et al. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001;158:635-7. (Pubitemid 32289829)
132. George TP, Vessicchio JC, Termine A et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53-61. (Pubitemid 34655556)
133. Banham L, Gilbody S. Smoking cessation in severe mental illness: what works? Addiction 2010;105:1176-89.
134. Hollen V, Ortiz G, Schacht L et al. Effects of adopting a smokefree policy in state psychiatric hospitals. Psychiatr Serv 2010;61:899-904.
135. Mansia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007;16:135-232.
136. Shaw MJ, Shaw L. The effectiveness of differing dental health education programmes in improving the oral health of adults with mental handicaps attending Birmingham adult training centres. Commun Dent Health 1991;8:139-45.
137. European Heart Rhythm Association; Heart Rhythm Society, Zipes DP et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2006;48:e247-346.
138. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008;23:201-9. (Pubitemid 351577689)
139. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005;80:1050-7. (Pubitemid 41099391)
140. Shim JC, Shin JG, Kelly DL et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007;164:1404-10. (Pubitemid 47461141)
141. Walters J, Jones I. Clinical questions and uncertainty - prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol 2008;22:82-9.
142. Trixler M, Gáti A, Fekete S et al. Use of antipsychotics in the management of schizophrenia during pregnancy. Drugs 2005;65:1193-206. (Pubitemid 41032046)
143. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009;15:183-92.
144. Miller LJ. Management of atypical antipsychotic drug-induced weight gain: focus on metformin. Pharmacotherapy 2009;29:725-35.
145. Corrigan PW, Larson JE, Rüsch N. Self-stigma and the "why try" effect: impact on life goals and evidence-based practices. World Psychiatry 2009;8:75-81.
146. Craddock N, Craddock B. Patients must be able to derive maximum benefit from a psychiatrist's medical skills and broad training. World Psychiatry 2010;9:30-1.
147. Hollins S. Bridging a cultural divide within medicine: a role for psychiatrists? World Psychiatry 2010;9:32-3.
148. Correll CU. From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25:S12-S21.
149. Millar H. Development of a health screening clinic. Eur Psychiatry 2010;25:S29-S33.
150. Druss BG, Zhao L, Von Esenwein SA et al. The Health and Recovery Peer (HARP) Program: a peer-led intervention to improve medical self-management for persons with serious mental illness. Schizophr Res 2010;118:264-70.